Real-World Experience Reported for Sequent Medical's WEB Device to Treat Cerebral Aneurysms

April 20, 2016—Christin Clajus, MD, et al have published findings demonstrating real-world experience in the use of all iterations of the Woven EndoBridge—WEB—cerebral aneurysm embolization device (Sequent Medical, Inc.) in ruptured and unruptured aneurysms. The WEB, which is available in Europe, is designed for treating wide-necked intracranial bifurcation aneurysms. The study is available online ahead of print in the Journal of NeuroInterventional Surgery.

As summarized in the Journal of NeuroInterventional Surgery, the study included 108 patients with 114 intracranial aneurysms, of which 47 (41.2%) were ruptured. Anatomic and clinical results were reported for all patients; 86 patients received angiographic and clinical follow-up after a mean of 13.4 months. 

The investigators reported that 110 of 114 WEB devices (96.5%) were deployed successfully. Thromboembolic complications occurred in 11 of 110 interventions (10%), with a new permanent deficit in one patient. Rerupture after WEB treatment was detected in two aneurysms (4.3%), both of which had initially presented with subarachnoid hemorrhage. Angiographic follow-up revealed adequate occlusion in 68 of 90 aneurysms (75.6%). Fifteen aneurysms required retreatment.

The investigators concluded that this series confirms a high level of safety and efficacy of the WEB device for the treatment of wide-necked intracranial aneurysms.

The WEB device has received European CE Mark approval. In the United States, it is an investigational device limited by law to investigational use.